Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy

Key Points

• Carteolol may serve as a promising dual-targeting therapeutic agent for colorectal cancer.
• In silico predictions indicate its ability to target both KRAS G12D and EGFR mutations.
• Computational repurposing methods analyze existing drugs for effective cancer treatment options.
• Further biochemical and cellular validation is essential to confirm its clinical relevance.